Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after Upfront chemotherapy: the role of single-agent rituximab.

Abstract	Currently no standard treatment exists for patients with posttransplant lymphoproliferative disorders relapsed or refractory to chemotherapy after failure of reduction in immunosuppression. We have analyzed the effects of single-agent rituximab treatment in eight patients (seven adult, one pediatric) in this setting. Three patients had been salvaged with rituximab several times. In the seven adults, rituximab salvage therapy achieved complete remission (CR) in three patients (43%) and partial remission in one (14%). In the pediatric patient, a PR was obtained that could be reinduced on relapse with repeated administrations of rituximab. Patients achieving CR either remained in CR or were successfully salvaged again with single-agent rituximab. At a median follow-up of 69 months, median progression-free survival was 9 months and no relevant therapy-associated toxicity was observed. Single-agent rituximab salvage therapy is an effective treatment option in this setting of intensively pretreated patients, with virtually no therapy-associated toxicity.
Authors	Ralf U Trappe, Sylvain Choquet, Petra Reinke, Martin Dreyling, Hans-Günther Mergenthaler, Ulrich Jäger, Christian Kebelmann-Betzing, Sven Jonas, Hans Lehmkuhl, Ioannis Anagnostopoulos, Véronique Leblond, Roland Hetzer, Bernd Dörken, Hanno Riess, Stephan Oertel
Journal	Transplantation (Transplantation) Vol. 84 Issue 12 Pg. 1708-12 (Dec 27 2007) ISSN: 0041-1337 [Print] United States
PMID	18165786 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References	Antibodies, Monoclonal Antibodies, Monoclonal, Murine-Derived Antineoplastic Agents Rituximab Vincristine Doxorubicin Cyclophosphamide Prednisone
Topics	Adult Antibodies, Monoclonal (therapeutic use) Antibodies, Monoclonal, Murine-Derived Antineoplastic Agents (therapeutic use) Antineoplastic Combined Chemotherapy Protocols (administration & dosage, therapeutic use) Cyclophosphamide (administration & dosage) Disease Progression Disease-Free Survival Doxorubicin (administration & dosage) Humans Immunosuppression Therapy Lymphoproliferative Disorders (complications, drug therapy, etiology) Neoplasms (drug therapy, mortality) Prednisone (administration & dosage) Rituximab Salvage Therapy Survival Analysis Survivors Treatment Failure Treatment Outcome Vincristine (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!